DPP-4抑制剂沙格列汀对糖尿病非酒精性脂肪肝的作用研究

目的 观察二肽基肽酶4(DPP-4)抑制剂沙格列汀对2型糖尿病合并非酒精性脂肪肝(NAFLD)的作用及疗效.方法 40例初发2型糖尿病合并NAFLD患者分为沙格列汀组和二甲双胍组,每组20例.在饮食和运动治疗基础上,沙格列汀组给予每天0.005 g沙格列汀,二甲双胍组给予每天0.85～1.70 g二甲双胍.观察两组患者治疗前和治疗后3个月的糖化血红蛋白(HbA1c)、三酰甘油(TG)、血压(BP)、丙氨酸氨基转移酶(ALT)、肝脏CT值及肝脏/脾脏CT比值.结果 治疗后3个月,两组的TG、ALT、肝脏CT值及肝脏/脾脏CT比值较治疗前差异有统计学意义(P＜0.05),两组比较差异无统计学意义(P＞0.05).结论 在糖尿病合并NAFLD的状态下,沙格列汀对减轻脂肪肝有一定的作用.

Effect of saxagliptin on nonalcoholic fatty liver in patients with diabetes mellitus

Objective To observe the effect and efficacy of DPP-4 inhibitor saxagliptin on nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus.Methods Forty patients with newly diagnosed with type 2 diabetes complicated with NAFLD were divided into two groups:the saxagliptin group and the metformin group.On the basis of dietary and exercise therapies,the saxagliptin group received 0.005 g of saxagliptin daily and the metformin treatment group received 0.85-1.70 g of metformin daily.The levels of glycosylated hemoglobin(HbA1 c),triglyceride (TG),blood pressure (BP),alanine aminotransferase (ALT),liver CT and liver/spleen CT were observed before and 3 months after treatment.Results After treatment for 3 months,the TG,ALT,liver CT and liver / spleen CT of the metformin group and the saxagliptin group were significantly higher than those before treatment(P＜0.05).There was no significant difference in the TG,ALT and liver CT values between the two groups(P＞ 0.05).Conclusion In the state of diabetes mellitus complicate with nonalcoholic fatty liver,saxagliptin has a certain effect on relieving fatty liver.